Papillary renal cell carcinoma is a type of kidney cancer that often causes no problems at first, but some people later notice blood in the urine, side or back pain, or tiredness. Many people first hear about papillary renal cell carcinoma after a scan done for another reason. The early symptoms of papillary renal cell carcinoma can be easy to miss, and it is most often found in adults, especially older adults. This cancer can stay limited to the kidney for some time, but if it spreads, it can become life-threatening and the outlook is less favorable. Treatment often includes surgery, and some people also need targeted drugs, immunotherapy, or careful monitoring depending on the size of the tumor and how far it has grown.
How many people live with Papillary renal cell carcinoma?
Worldwide, about 1.6 million people were living after a kidney cancer diagnosis made in the past 5 years (IARC GLOBOCAN, 2022); because papillary renal cell carcinoma is estimated to make up about 10% to 15% of kidney cancers (National Cancer Institute, 2024), this suggests roughly 160,000 to 240,000 people worldwide are living with this type, although that is an estimate rather than a direct count. In the United States, about 615,000 people were living with kidney and renal pelvis cancer (NCI SEER, 2024), which suggests roughly 62,000 to 92,000 people with papillary renal cell carcinoma here as well, again as an estimate rather than a direct count.
Overview
Papillary renal cell carcinomaSymptoms
Papillary renal cell carcinoma may cause blood in the urine, side or back pain, and tiredness. Early symptoms of papillary renal cell carcinoma can be mild or absent, so some people only notice weight loss, fever, or a belly lump later.
Outlook and prognosis
Outlook for papillary renal cell carcinoma often depends on the stage, tumor size, and whether it has spread. Many people do well when it is found early and treated, while advanced papillary renal cell carcinoma usually needs closer follow-up and longer-term treatment.
Causes and risk factors
Papillary renal cell carcinoma is linked to smoking, excess body weight, long-term kidney failure, and being older. Risk can also rise with inherited gene changes, especially in families with hereditary papillary kidney cancer, and may be higher in men.
Genetic influences
Genetics are important in papillary renal cell carcinoma. Some cases happen by chance, while others are linked to inherited gene changes or tumor gene variants that can affect risk, family screening, and treatment choices.
Diagnosis
Papillary renal cell carcinoma is often suspected when an ultrasound, CT, or MRI shows a kidney mass, sometimes during a scan for something else. Diagnosis is confirmed by examining tumor tissue, while tests help assess kidney function and plan treatment.
Treatment and drugs
Papillary renal cell carcinoma is often treated with surgery to remove part or all of the kidney. If it has spread, treatment may include targeted drugs, immunotherapy, or both. Care also includes scans and regular follow-up.
Symptoms
Papillary renal cell carcinoma often causes no symptoms at first and may be found on a scan done for another reason. You might notice small changes at first, but the early symptoms of papillary renal cell carcinoma are often subtle and can look like other common problems. As it grows, it can cause blood in the urine, one-sided back or side pain, unusual tiredness, weight loss, or symptoms if it spreads to other parts of the body.
Urine may look pink, red, brown, or cola-colored, though sometimes the blood is too small to see. This can come and go, so even one episode should be checked.
A dull ache or pressure in the side, lower back, or under the ribs can happen when the kidney area becomes irritated. The pain is often on one side and may not improve as expected.
Some people notice a lump, swelling, or a heavy feeling in the belly or side. This may become more noticeable when getting dressed, bending, or lying on that side.
Many living with papillary renal cell carcinoma feel unusually tired, weak, or short of breath with routine activity. This can happen when the cancer leads to low red blood cells, also called anemia.
How people usually first notice Papillary renal cell carcinoma?
Papillary renal cell carcinoma is often first noticed by accident, after an imaging test such as an ultrasound or CT scan done for another reason, because many people have no symptoms early on. When symptoms do appear, the first signs of papillary renal cell carcinoma can include blood in the urine, pain or pressure in the side or lower back, tiredness, unexplained weight loss, fever, or a lump that may be felt in the abdomen, although not everyone has the classic combination. Because these symptoms can also happen with far more common and less serious problems, they do not automatically mean cancer, but persistent blood in the urine or ongoing flank pain should be checked by a doctor.
Types of Papillary renal cell carcinoma
Papillary renal cell carcinoma can show up in more than one pattern, and the differences are mostly based on how the tumor cells look under the microscope. Symptoms don’t always look the same for everyone. In everyday life, many living with papillary renal cell carcinoma may notice no symptoms at first, while others develop blood in the urine, side or back pain, tiredness, or unexplained weight loss as the cancer grows. The main types of papillary renal cell carcinoma that doctors have traditionally described are type 1 and type 2, and type 2 often behaves more aggressively.
Type 1
Type 1 papillary renal cell carcinoma often grows more slowly and may be found by chance on a scan done for another reason. When symptoms do happen, they can include blood in the urine, a dull ache in the side, or a belly mass, but some people have few signs until the tumor gets larger.
Type 2
Type 2 papillary renal cell carcinoma is more likely to act aggressively, so symptoms may appear sooner or become more noticeable over time. Some may find that pain, visible blood in the urine, fatigue, weight loss, or signs related to spread outside the kidney are more common with this type.
Can I slow down the onset of symptoms?
Probably not in a proven way: for papillary renal cell carcinoma, a type of kidney cancer, there is no well-established lifestyle change or medicine that has been shown to reliably delay when symptoms begin. Not smoking, keeping a healthy weight, staying active, and controlling blood pressure may lower overall kidney cancer risk and support kidney health, but they have not been proven to prevent this cancer or postpone symptoms once it starts. If this cancer runs in your family or you have a known inherited risk, your doctor may suggest regular kidney scans to look for changes before symptoms appear, and while that cannot stop the cancer, it can help catch it earlier.
What genetics can tell you about symptoms
Genetics can sometimes help explain how papillary renal cell carcinoma shows up and when it starts, especially in families with inherited changes in genes linked to kidney cancer, where tumors may develop at a younger age or affect both kidneys. These genetic differences do not usually predict day-to-day symptoms very precisely, but they can be linked to a higher chance of developing multiple tumors and, in some cases, a different pattern of growth or aggressiveness. For many people, symptoms still depend more on the size and location of the tumor than on genetics alone, so genetic results are usually used alongside scans, family history, and other test findings.
Causes and risk factors
Papillary renal cell carcinoma usually develops when kidney cells build up DNA changes over time. A family history or an inherited gene change can raise the chance of papillary renal cell carcinoma, but many people develop it without a known inherited cause. Smoking, excess body weight, high blood pressure, and long-term kidney disease or dialysis are important risk factors for papillary renal cell carcinoma. It is rarely just one factor, and the mix matters. Older age, being male, and long-term exposure to certain workplace chemicals may also add to the risk.
What are the most common causes or risk factors?
For most people, there is no single clear cause of papillary renal cell carcinoma, a type of kidney cancer, but the strongest risk factors are smoking, excess body weight, high blood pressure, older age, being male, and long-term kidney disease, especially if dialysis is needed. Risk is also higher in some families, either because kidney cancer runs in the family or because of rare inherited gene changes that make this cancer more likely. Having one or even several of these risk factors does not mean someone will definitely develop it, and some people get it without any known risk factors.
Environmental and biological risk factors
Papillary renal cell carcinoma is a type of kidney cancer, and its risk is shaped by both body-based factors and outside exposures. Doctors often group risks into internal (biological) and external (environmental). When people ask about risk factors for papillary renal cell carcinoma, the strongest known ones include older age, male sex, kidney disease, and certain workplace chemicals. Having one or more of these risk factors does not mean you will develop it.
Papillary renal cell carcinoma becomes more common later in adult life. This likely reflects years of slow cell damage and repair in kidney tissue.
People assigned male at birth develop this cancer more often than people assigned female at birth. Hormonal and other body-based differences may play a role, although the exact reason is not fully clear.
Long-term kidney damage and reduced kidney function raise the risk of papillary renal cell carcinoma. Ongoing inflammation and repeated tissue repair may make abnormal cell growth more likely.
People on long-term dialysis can develop many kidney cysts, called acquired cystic kidney disease. These changes increase the chance of papillary renal cell carcinoma and other kidney tumors.
Genetic risk factors
Most papillary renal cell carcinoma happens sporadically, but some cases are tied to inherited DNA changes or a strong family history. Family history and rare inherited syndromes are among the clearest genetic risk factors for papillary renal cell carcinoma, especially when several relatives are affected. Carrying a genetic change doesn’t guarantee the condition will appear. Doctors often think about genetic counseling when kidney cancer shows up at a younger age, in both kidneys, or in multiple family members.
Family history: Having a parent, sibling, or child with kidney cancer can raise the chance of papillary renal cell carcinoma, especially if more than one relative is affected. A family pattern is more concerning when cancer starts young or appears in both kidneys.
MET changes: Inherited changes in the MET gene cause hereditary papillary renal carcinoma, a rare syndrome strongly linked to type 1 papillary tumors. Many people with this syndrome develop more than one tumor or tumors in both kidneys over time.
FH changes: Inherited changes in the FH gene cause hereditary leiomyomatosis and renal cell cancer, which can include papillary renal cell carcinoma or a closely related kidney cancer. These cancers often appear at a younger age and may grow or spread faster than typical cases.
Tumor DNA changes: Some papillary renal cell carcinomas are driven by DNA changes that happen only in the kidney tumor as it forms, rather than being inherited. Extra copies of certain chromosomes and changes affecting MET are well-known examples, especially in type 1 papillary tumors.
Lifestyle risk factors
Several modifiable habits are linked to the development and progression of papillary renal cell carcinoma, even though not every case is tied to lifestyle. The most important lifestyle risk factors for papillary renal cell carcinoma overlap with those for kidney cancer more broadly, especially smoking, excess body weight, and low physical activity. Diet, alcohol patterns, and long-term use of certain pain medicines may also play a role. Addressing these factors may help lower risk and support overall kidney health.
Cigarette smoking is one of the clearest lifestyle factors associated with renal cell cancers, including papillary subtypes. The risk tends to rise with heavier and longer-term tobacco exposure, and it may fall gradually after quitting.
Overweight and obesity are linked to a higher risk of kidney cancer through hormonal, inflammatory, and metabolic effects. Carrying excess body fat can also worsen related problems such as high blood pressure and insulin resistance, which may further stress the kidneys.
A sedentary lifestyle is associated with poorer metabolic health and higher body weight, both of which are relevant to papillary renal cell carcinoma risk. Regular physical activity may help lower risk indirectly by improving weight control, blood pressure, and insulin sensitivity.
Diets high in ultra-processed foods, excess calories, and large amounts of processed or red meat may contribute to obesity and adverse metabolic changes that increase kidney cancer risk. In contrast, eating patterns centered on vegetables, fruits, legumes, and whole grains may support healthier weight and cardiometabolic function.
Risk prevention
Papillary renal cell carcinoma cannot always be prevented, but some steps may lower the chance of developing it or help catch kidney cancer earlier when treatment is easier. The strongest day-to-day risks people can work on are smoking, excess body weight, and poorly controlled blood pressure. Prevention works best when combined with regular check-ups. This matters even more for people with a strong family history of kidney cancer or an inherited risk condition.
Smoking raises the risk of papillary renal cell carcinoma and other kidney cancers. Quitting can lower that risk over time, even if you have smoked for years.
Carrying excess body weight can increase the risk of papillary renal cell carcinoma. Steady habits like regular activity and balanced meals can help lower risk and support overall kidney health.
High blood pressure is linked with a higher risk of kidney cancer, including papillary renal cell carcinoma. Keeping it in a healthy range with lifestyle changes and medicine when needed may help reduce risk.
Long-term heavy use of some pain relievers can harm the kidneys and may raise cancer risk. Use over-the-counter pain medicine carefully and ask your doctor if you need it often.
Can you prevent Papillary renal cell carcinoma?
You cannot fully prevent papillary renal cell carcinoma, which is a type of kidney cancer, and some people develop it even without clear risk factors. Still, lowering well-known risks may help: not smoking, keeping a healthy weight, and managing high blood pressure can all support kidney health. If this cancer runs in your family or you have an inherited risk, regular checkups may help find problems early, but they cannot guarantee prevention.
Transmission
Papillary renal cell carcinoma is not infectious, so it cannot be caught from someone else through touching, kissing, sex, coughing, shared food, or blood. Being around someone living with papillary renal cell carcinoma does not put you at risk.
In most cases, papillary renal cell carcinoma is not passed down in families and develops because changes build up in kidney cells over time. Still, a small number of people have an inherited risk, so if several close relatives have had kidney cancer or it appeared at a younger age, genetic counseling can help explain how papillary renal cell carcinoma is inherited in those rare families.
When to test your genes
Consider genetic testing if papillary renal cell carcinoma occurs at a young age, runs in your family, affects both kidneys, or appears in several tumors at once. Testing can uncover inherited syndromes, guide screening for relatives, and sometimes help tailor treatment, especially when targeted therapy is being considered.
Diagnosis
Papillary renal cell carcinoma is often found after blood in the urine, side pain, anemia, or a kidney mass leads to testing, although some people learn about it after a scan done for something else. Doctors usually begin with a review of symptoms, an exam, and imaging to look closely at the kidneys. The diagnosis of papillary renal cell carcinoma is then confirmed by looking at tumor cells under a microscope, especially when treatment planning depends on the exact tumor type.
Doctors ask about blood in the urine, side or back pain, tiredness, weight loss, and how long symptoms have been going on. A physical exam may also check for high blood pressure, swelling, or a lump in the abdomen.
Urine testing can look for blood or signs of infection that might explain symptoms. Blood tests check kidney function, blood counts, and sometimes calcium or liver-related changes, and other lab tests may help rule out common conditions.
Ultrasound may be the first test if there is blood in the urine or pain, but CT scans are often the main imaging test for a suspected kidney tumor. MRI may be used instead when more detail is needed or when contrast dye for CT is not a good option.
A CT scan with contrast can show the size of the kidney mass, whether it has grown into nearby veins, and whether there are enlarged lymph nodes. These imaging findings help doctors judge how likely papillary renal cell carcinoma is and plan the next step.
How is Papillary renal cell carcinoma diagnosed?
Papillary renal cell carcinoma, a type of kidney cancer, is usually first suspected when an imaging test such as an ultrasound, CT scan, or MRI shows a growth in the kidney, often after symptoms like blood in the urine or side pain lead to testing. Doctors may also do urine and blood tests to check for bleeding, low red blood cell levels, and how well the kidneys are working, but the diagnosis is usually confirmed by looking at a sample of the tumor under a microscope, either from a biopsy or after surgery. If there is a strong family history or signs that the cancer may be part of an inherited condition, genetic testing may also be offered.
Stages of Papillary renal cell carcinoma
For many, the first step comes when usual activities start to feel different, such as blood in the urine, ongoing side or back pain, or tiredness that does not ease up. In papillary renal cell carcinoma, doctors describe the cancer by stage rather than by symptoms alone. The stages of papillary renal cell carcinoma are based on how large the tumor is and whether it has spread to nearby tissues, lymph nodes, or other parts of the body.
Stage 1
The tumor is limited to the kidney and is 7 centimeters (about 2.8 inches) or smaller. Many people have no symptoms at this stage, and it may be found during a scan done for another reason.
Stage 2
The tumor is still only in the kidney but is larger than 7 centimeters (about 2.8 inches). Some people may start to notice signs such as blood in the urine, pain in the side, or a lump, but symptoms can still be mild or absent.
Stage 3
The cancer has grown into nearby major veins, nearby tissue around the kidney, or nearby lymph nodes, but it has not spread to distant organs. Day to day, this can mean more noticeable pain, fatigue, weight loss, or swelling.
Stage 4
The cancer has spread beyond the kidney area to distant parts of the body, such as the lungs, bones, liver, or brain, or it has grown past nearby boundaries in a more advanced way. Symptoms often depend on where it has spread, so some may have breathing problems, bone pain, or more severe tiredness.
Outlook and prognosis
The outlook for papillary renal cell carcinoma is often favorable when the tumor is found early and confined to the kidney, with many patients cured by surgery. Prognosis depends mainly on stage, tumor grade, whether lymph nodes or distant organs are involved, and the subtype, with type 1 papillary renal cell carcinoma generally associated with better outcomes than type 2. Localized disease has a substantially higher survival rate than metastatic disease, while recurrence risk rises with larger, higher-grade, or more advanced tumors. When papillary renal cell carcinoma has spread beyond the kidney, it is harder to cure, but targeted therapies, immunotherapy, and sometimes clinical trials can help control the cancer and prolong survival. Mortality is therefore low for many patients with small, localized tumors but becomes significantly higher in advanced or treatment-resistant cases. Careful follow-up with imaging and clinical monitoring is important because some tumors can recur even after apparently successful treatment.
Long-term effects
For many people, the long-term effects of papillary renal cell carcinoma depend on the stage of the cancer, whether it has spread, and how much kidney tissue is affected or removed during treatment. Thinking about the long-term effects helps set expectations for recovery, follow-up scans, and day-to-day health over time. Some people do very well after treatment, while others need ongoing care for cancer that returns or continues to grow. Even when the early symptoms of papillary renal cell carcinoma seemed mild, the outlook can still vary widely from one person to another.
If part or all of a kidney is removed, long-term kidney function can drop. Many living with papillary renal cell carcinoma still do well with one kidney, but some develop chronic kidney disease, especially if the other kidney is not fully healthy.
Papillary renal cell carcinoma can sometimes come back after surgery, either in the kidney area or elsewhere in the body. This is why people often need imaging and checkups for years, even when treatment first seems successful.
When the cancer spreads, long-term effects may include pain, weight loss, fatigue, or problems linked to the organ involved, such as the lungs, liver, bones, or brain. In these cases, treatment often focuses on controlling the cancer and preserving quality of life for as long as possible.
Tiredness can last for months after surgery, targeted treatment, or immunotherapy. For many, symptoms improve gradually, but some may find low energy continues to affect work, exercise, and daily routines.
How is it to live with Papillary renal cell carcinoma?
Living with papillary renal cell carcinoma can feel unsettling because many people have no symptoms at first, while others are coping with fatigue, pain in the side or back, blood in the urine, and the emotional weight of scans, appointments, and uncertainty. Daily life often shifts around treatment and recovery, with energy levels that may rise and fall, so work, exercise, sleep, and family routines may need to be adjusted for a time. It also affects the people around you: loved ones may take on practical tasks, come to visits, and carry their own worry, which is why clear communication, support, and small routines can make life feel more manageable for everyone.
Treatment and drugs
Papillary renal cell carcinoma is treated mainly based on how large the tumor is, whether it has spread, and how well the kidneys are working. For many people, treatment starts with surgery to remove part or all of the kidney tumor, especially when the cancer is still limited to one area. Treatment often looks different for each person, and if papillary renal cell carcinoma has spread or surgery is not the best option, doctors may use targeted drugs, immunotherapy that helps the immune system attack cancer, or sometimes careful monitoring for slow-growing tumors. In advanced disease, the best treatment for papillary renal cell carcinoma may involve more than one approach over time, with regular scans and follow-up visits to check how well treatment is working and watch for side effects.
Can you cure Papillary renal cell carcinoma?
Papillary renal cell carcinoma, a type of kidney cancer, can sometimes be cured if it is found early and fully removed with surgery. If it has spread or cannot be removed completely, there is usually no sure cure, but treatment may still help shrink the cancer, slow its growth, and ease symptoms. Your outlook can vary depending on the size of the cancer, whether it has spread, and your overall health.
Non-drug treatment
For many living with papillary renal cell carcinoma, treatment often centers on procedures, monitoring, and supportive care rather than medicines alone. Not every approach works the same way, because the best plan depends on tumor size, whether the cancer has spread, kidney function, and overall health. Some people need a procedure right away, while others with a small tumor may be safely followed for a time with regular scans. The goal is to control the cancer, protect kidney tissue when possible, and help you feel as well as possible day to day.
Surgery is often the main non-drug treatment for papillary renal cell carcinoma when the tumor can be removed. Many people have either part of the kidney removed or the whole kidney removed, depending on the tumor’s size, location, and how well the other kidney works.
For some small kidney tumors, careful monitoring with scans and checkups may be safer than immediate treatment. This can be an option for older adults, people with major health problems, or those whose tumor appears to be growing very slowly.
Ablation destroys the tumor with extreme heat or cold through a needle placed into the kidney, usually guided by imaging. It may be used as a non-surgical treatment for papillary renal cell carcinoma when surgery is not a good fit or when the tumor is small.
Radiation is not usually the main treatment for the kidney tumor itself, but it can help control pain or other symptoms if the cancer has spread. For example, if a bone metastasis makes walking painful, targeted radiation may shrink that spot and improve comfort.
Your genes may have an impact on how drugs work for you
For people living with papillary renal cell carcinoma, gene differences can sometimes affect how well certain cancer medicines work, especially treatments chosen to target changes found in the tumor itself. In day-to-day care, this can mean one person’s cancer may shrink or stay controlled longer with a given treatment, while another person may get less benefit or have more side effects, even when they take the same medicine. Doctors may use tumor gene testing to help guide treatment choices in some cases, but inherited gene testing to predict medicine response is not yet a routine part of care for most people with this cancer.
Pharmacological treatments
Drug treatment for papillary renal cell carcinoma is used most often when the cancer has spread, cannot be removed fully with surgery, or comes back after treatment. Many people find relief when the right medicine slows tumor growth or helps keep the disease stable, although the best choice depends on the tumor’s features, overall health, and any prior treatments. For many living with papillary renal cell carcinoma, doctors often favor targeted drugs or immunotherapy rather than standard chemotherapy. Because this is a less common kidney cancer type, treatment for papillary renal cell carcinoma is sometimes guided by smaller studies and specialist experience.
Cabozantinib is a targeted drug that blocks signals cancers use to grow new blood vessels and spread. It is often a leading first treatment for advanced papillary renal cell carcinoma because it has shown better cancer control than some older options.
Sunitinib is another targeted treatment that slows growth signals and blood vessel formation in the tumor. It may still be used in some cases, especially if cabozantinib is not a good fit or is not available.
Pembrolizumab is an immunotherapy drug that helps the immune system recognize and attack cancer cells. Some people with papillary renal cell carcinoma may receive it alone or as part of a treatment plan when immunotherapy is considered appropriate.
Nivolumab is another immunotherapy medicine, and in some cases it is paired with ipilimumab or with cabozantinib. If one option is not effective, second-line or alternative drugs may be offered based on how the cancer responds and what side effects occur.
Genetic influences
When papillary renal cell carcinoma shows up in more than one close relative, it can raise questions about inherited risk. It’s natural to ask whether family history plays a role. Most people with papillary renal cell carcinoma do not have a clear inherited cause, but genetics can still matter, and a small number of families carry gene changes that strongly raise risk, especially in genes such as MET or FH that affect how kidney cells grow and divide.
For many living with this cancer, the main practical issue is whether the diagnosis is part of a broader family pattern rather than a one-time event. These genetic risk factors for papillary renal cell carcinoma are more likely to be considered when cancer develops at a younger age, affects both kidneys, or appears alongside related tumors in the family. In those situations, genetic counseling and sometimes genetic testing can help clarify risk for you and your relatives, and may guide screening and follow-up care.
Is Papillary renal cell carcinoma genetic?
Genetics are important in papillary renal cell carcinoma. Some cases happen by chance, while others are linked to inherited gene changes or tumor gene variants that can affect risk, family screening, and treatment choices.
Having a genetic risk is not necessarily a diagnosis
Changes in genes are a normal part of being human and are widespread across the population. Most of these changes do not directly affect health and simply contribute to the natural differences seen among people. For many genes, having a change associated with a condition points to a possible link, not a certain diagnosis, particularly when several genes and environmental factors play a role. In some situations, though, one well-studied change in a particular gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
Two people with papillary renal cell carcinoma can be offered different treatments, even when their scans look similar, because the cancer may be driven by different gene changes. When doctors test the tumor, and sometimes a blood sample, they may look for changes such as MET alterations; Genetics is only one factor, but this information can help show whether a MET-directed treatment might be worth considering, often in selected cases or clinical trials, while drugs like cabozantinib are used more broadly because they block several cancer-growth signals. This matters even more when kidney cancer runs in the family or shows up at a younger age, since an inherited gene change can affect treatment choices and whether relatives should consider genetic counseling and screening.
Not every papillary renal cell carcinoma has a clear drug target, so immunotherapy and other standard treatments may still be the best option, depending on how far the cancer has spread, overall health, and what treatment has already been tried. For many living with papillary renal cell carcinoma, a common question is how genetic testing can guide papillary renal cell carcinoma treatment, and the answer is usually that it helps narrow the options rather than giving a simple yes-or-no result.
Interactions with other conditions
Papillary renal cell carcinoma often appears in the middle of other kidney and general health problems, which can make symptoms and treatment harder to sort out. People with papillary renal cell carcinoma may also have chronic kidney disease, and if kidney function is already reduced, surgery or other treatment may need to be planned more carefully to preserve as much kidney function as possible. Another important aspect is how it may link with other diseases: this cancer is seen more often in some inherited conditions, especially hereditary papillary renal cancer and hereditary leiomyomatosis and renal cell cancer, so a strong family history can matter. In day-to-day life, this might mean someone is being followed for kidney cysts, high blood pressure, or long-term kidney problems and then a scan finds a tumor unexpectedly. Diabetes, heart disease, and other long-standing conditions do not cause papillary renal cell carcinoma directly, but they can affect which treatments are safest and how well the body recovers. If there is a personal or family pattern of kidney tumors, fibroids, or early symptoms of papillary renal cell carcinoma, doctors may suggest genetic counseling or closer screening for related problems.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Papillary renal cell carcinoma?
Other kidney cancers and some noncancerous kidney growths or cysts can look similar to papillary renal cell carcinoma, especially on a scan. Kidney stones, urinary tract infections, kidney infections, and sometimes bladder cancer can also cause overlapping signs such as blood in the urine, pain in the side or back, tiredness, or unexplained weight loss.
History
People living with papillary renal cell carcinoma often first hear the name after a scan done for blood in the urine, ongoing side pain, or an unexpected finding during a check for something else. That can make it feel sudden, but this kidney cancer has been recognized and studied for many years as doctors learned that not all kidney tumors behave the same way.
In the 19th and early 20th centuries, doctors mainly described kidney cancers by what they looked like under the microscope or during surgery. As medical science evolved, pathologists began to notice that some tumors had small finger-like growth patterns, which helped set papillary renal cell carcinoma apart from other forms of kidney cancer. Early classification was imperfect, and some tumors that would now be grouped separately were once placed together, simply because imaging and lab methods were much more limited than they are today.
By the later 20th century, better microscopy, imaging, and cancer registries made the picture clearer. Researchers recognized papillary renal cell carcinoma as a distinct subtype of renal cell carcinoma rather than just a variation of a broader kidney cancer category. Over time, doctors also learned that it can show up in different ways: in some people it causes symptoms such as blood in the urine, tiredness, or flank discomfort, while in others the early symptoms of papillary renal cell carcinoma may be absent and the tumor is found incidentally.
More recently, advances in genetics and tumor biology have helped explain why papillary renal cell carcinoma can vary from one person to another. This work also showed that what looks like one disease under the microscope may include tumors with different biological behavior, which is one reason treatment planning now takes a more tailored approach. Today, the history of papillary renal cell carcinoma reflects a broader shift in cancer care: moving from simple visual description toward more precise diagnosis, clearer subtypes, and treatment decisions based on the features of the individual tumor.